- Current report filing (8-K)
August 15 2012 - 12:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported)
August 15, 2012
ACCELR8
TECHNOLOGY CORPORATION
(Exact name of registrant as specified in
its charter)
COLORADO
(State or other jurisdiction of incorporation)
0-11485
|
84-1072256
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
7000 North Broadway, Building 3-307, Denver, CO
|
80221
|
(Address of principal executive offices)
|
(Zip Code)
|
(303)
863-8808
(Registrant’s telephone number, including
area code)
Not
applicable
(Former name or former address, if changed
since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 10, 2012, the board of directors (the “Board”)
of Accelr8 Technology Corporation (the “Company”) appointed Steve Reichling to serve as the Company’s Chief Financial
Officer. Prior to joining the Company, Mr. Reichling served as general manager of Spring Bioscience Corp., a R&D and research
products subsidiary of Roche Tissue Diagnostics. From January 2003 to December 2009, Mr. Reichling held various finance, accounting
and operations leadership roles at Roche Tissue Diagnostics and Ventana Medical Systems, Inc., including director of finance and
operations, manager of business development finance, and head of Internal Audit and Sarbanes Oxley Compliance. From October 2002
to January 2003, Mr. Reichling was an auditor at Ernst & Young LLP. Mr. Reichling received his B.A. in accounting and entrepreneurship
from the University of Arizona and is a Certified Public Accountant.
Mr. Reichling will be paid an annual base salary of $170,000
and, in addition, will be provided with a budget of $70,000 for relocation expenses and temporary living arrangements. Additionally,
Mr. Reichling will be granted 200,000 non-qualified stock options to purchase shares of the Company’s common stock at an
exercise price equal to the closing price of the Company’s common stock on the date of the grant. The options will vest over
a five year period with 40% vesting two years from the date of grant, and the remaining vesting in equal monthly installments thereafter.
Mr. Reichling will receive the Company’s standard benefit package including health care and life and disability insurance,
and will be eligible to receive cash bonuses if and when the Board adopts such a plan.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
None
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: August 15, 2012
|
ACCELR8 TECHNOLOGY CORPORATION
(Registrant)
/s/ Lawrence Mehren _____________
Lawrence Mehren
Chief Executive Officer
|
|
|
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024